natgillin/translations-raw huggingface dataset:
Approximately 12 to 21 % of children treated with ribavirin and interferon alfa-2b (pegylated and non pegylated) developed increase in thyroid stimulating hormone (TSH).
Pri približno 12 % do 21 % otrok, zdravljenih z ribavirinom in interferonom alfa-2b (pegiliranim in nepegiliranim), se je pojavilo povečanje tiroidee stimulirajočega hormona (TSH).
Approximately 12 to 21% of children treated with ribavirin and interferon alfa-2b (pegylated and non pegylated) developed increase in thyroid stimulating hormone (TSH).
Pri približno 12 % do 21 %otrok, zdravljenih z zdravilom ribavirin in interferonom alfa-2b (pegiliranim in nepegiliranim), se je pojavilo povečanje tiroidee stimulirajočega hormona (TSH).
Approximately 12% of subjects in the Phase III study in patients with newly diagnosed CML in chronic phase and approximately 30% of subjects in the Phase II study in patients with imatinib- resistant or intolerant CML in chronic phase and accelerated phase were 65 years of age or over.
Približno 12 % oseb v študijah faze III pri bolnikih z novo odkrito KML v kronični fazi in približno 30 % oseb v študijah faze II pri bolnikih z rezistenco na imantinib ali neprenašanjem imatiniba v kronični ali pospešeni fazi KML je bilo starih 65 let ali več.
Approximately 15 to 25% of patients in phase III studies had psoriatic arthritis (PsA) at baseline.
Približno 15 do 25% bolnikov v študijah faze III je imelo ob izhodišču psoriatični artritis.
Approximately 15% of the administered TRISENOX dose is excreted in the urine as unchanged AsIII.
Približno 15 % apliciranega odmerka zdravila TRISENOX se izloči v seču kot nespremenjen AsIII.
Approximately 17 % of cardiac dysfunction related events occurred after completion of Herceptin.
Približno 17 % srčnih končnih ciljev je nastopilo po zaključku zdravljenja z zdravilom Herceptin.
Approximately 2.8% (11/386 patients) of Perjeta-treated patients and 6.2% (23/372 patients) of placebo-treated patients tested positive for ATAs.
Pozitiven izvid testiranja ATA je imelo 2,8 % bolnikov (11/386 bolnikov) v skupini, zdravljeni z zdravilom Perjeta, in 6,2 % (23/372 bolnikov) v skupini, zdravljeni s placebom.
Approximately 20 % was excreted as total topotecan and 2 % was excreted as N-desmethyl topotecan in the urine.
V urinu se je izločilo približno 20 % v obliki celotnega topotekana in 2 % v obliki N-dezmetiltopotekana.
Approximately 20% of a timolol dose is excreted in the urine unchanged and the remainder excreted in urine as metabolites.
Približno 20% odmerka timolola se izloči s sečem v nespremenjeni obliki, preostanek pa v obliki presnovkov.
Approximately 20% of a timolol dose is excreted in the urine unchanged and the remainder excreted in urine as metabolites.
Približno 20% odmerka timolola se izloči v seč v nespremenjeni obliki, preostali del pa v obliki presnovkov.
Approximately 22.4% of patients treated with Sivextro in Phase 3 clinical studies (n= 662) experienced at least one treatment-emergent adverse reaction.
Pri približno 22,4 % bolnikov, zdravljenih z zdravilom Sivextro v kliničnih študijah 3. faze (n = 662), se je pojavil vsaj en neželeni učinek, povezan z zdravljenjem.
Approximately 22.4% of patients treated with Sivextro in Phase 3 clinical studies (n=662) experienced at least one treatment-emergent adverse reaction.
Pri približno 22,4 % bolnikov, zdravljenih z zdravilom Sivextro v kliničnih študijah 3. faze (n = 662), se je pojavil vsaj en neželeni učinek, povezan z zdravljenjem.
Approximately 24 - 72 hours after injection, a finger extension procedure may be performed, as necessary, to facilitate cord disruption.
Približno 24 – 72 ur po injiciranju lahko začnete izvajati postopek iztegovanja prstov, kot bo potrebno, da boste pospešili prekinitev vozliča.
Approximately 30 % of patients will also experience reactions at the injection site, predominantly mild inflammation or erythema.
Približno 30 % bolnikov bo izkusilo tudi reakcije na mestu injiciranja, pretežno blago vnetje ali eritem.
Approximately 30 ml of water
približno 30 ml vode
Approximately 30% of study participants carried diagnoses other than ALS and MS, including stroke, traumatic brain injury, Parkinson’s disease, Alzheimer’s disease and other dementia, primary lateral sclerosis, progressive bulbar palsy, and progressive supranuclear palsy.
Približno 30 % udeležencev študije je imelo diagnozo, ki ni bila ALS ali MS, vključno z možgansko kapjo, travmatsko poškodbo možganov, Parkinsonovo boleznijo, Alzheimerjevo boleznijo in drugimi demencami, primarno lateralno sklerozo, progresivno bulbarno paralizo in progresivno supranuklearno paralizo.
Approximately 30% of the administered radioactive dose was eliminated in the faeces over 9 days, of which less than 10% was intact drug.
Približno 30 % apliciranega radioaktivnega odmerka se je izločilo v blatu v 9 dneh; manj kot 10 % od tega je bilo nespremenjenega zdravila.
Approximately 30% of the medicinal product in the body was removed during a single 4-hour dialysis session.
Približno 30 % zdravila v telesu je bilo odstranjenega v enem 4-urnem ciklu dialize.
Approximately 33% of the administered radioactive dose was excreted in urine, mainly as
Približno 33% danega radioaktivno označenega odmerka se je izločilo z urinom, največ v obliki
Approximately 35% of subjects were chronic kidney disease (CKD) stage 1, 48% CKD stage 2, and 17% CKD stage 3 (eGFRCKD-EPI).
Približno 35 % oseb je imelo kronično ledvično bolezen 1. stopnje, 48 % kronično ledvično bolezen 2. stopnje in 17 % kronično ledvično bolezen 3. stopnje (eGFRCKD-EPI).
Approximately 38% of the treated patients with a stoma (an artificial opening at the front of the abdomen to collect faeces or urine from the body) experienced stoma complications such as swelling of the stoma.
Pri približno 38 % zdravljenih bolnikov s stomo (umetno odprtino na sprednji strani trebuha za zbiranje blata in urina iz telesa) je prišlo do zapletov, kot je oteklina stome.
Approximately 4.5% of patients can be expected to experience adverse reactions associated with the use of OPATANOL; however, only 1.6% of patients discontinued from the clinical studies due to these adverse reactions.
Pri približno 4,5% bolnikov lahko pričakujemo pojav neželenih učinkov, povezanih z uporabo zdravila OPATANOL, vendar je zaradi teh neželenih učinkov v kliničnih študijah prenehalo sodelovati le 1,6% bolnikov.
Approximately 44% of an oral dose is recovered in the urine over 24 hours, with only 3.6% of the dose excreted as parent drug substance.
Približno 44% peroralnega odmerka se izloči v urin v 24 urah, od tega le 3,6% v obliki matične zdravilne učinkovine.
Approximately 50 % of the animals treated with the unformulated active substance showed erythema after challenging the induced animals.
Pri približno 50 % živali, ki so jim dajali neformulirano zdravilno učinkovino, se je po dajanju odmerka pojavil eritem.
Approximately 50% of patients were in functional Class III.
Približno 50 % teh bolnikov je bilo v funkcijskem razredu III.
Approximately 51 % was excreted as total topotecan and 3% was excreted as N-desmethyl topotecan in the urine.
Z urinom se izloči približno 51 % skupnega topotekana in 3 % N-desmetil topotekana.
Approximately 52% of the patients treated with Revestive experienced adverse reactions (versus 36% of the patients given placebo).
Pri približno 52 % bolnikov, zdravljenih z zdravilom Revestive, so se pojavile neželeni učinki (v primerjavi s 36 % bolnikov s placebom).
Approximately 54% of patients initiating treatment at the recommended dose of 750 mg required at least one dose adjustment due to adverse reaction, with a median time to first dose reduction of approximately 7 weeks.
Približno 54 % bolnikov, ki so začeli zdravljenje s priporočenim odmerkom 750 mg, je potrebovalo najmanj eno prilagajanje odmerka zaradi neželenega učinka, pri čemer je bila mediana časa do prvega znižanja odmerka približno 7 tednov.
Approximately 60% of cinacalcet-treated patients achieved a ≥ 30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels.
Približno 60% s cinakalcetom zdravljenih bolnikov je doseglo ≥ 30% znižanje koncentracije iPTH; tak učinek je bil dosleden prek spektra različnih izhodiščnih koncentracij iPTH.
Approximately 60% of cinacalcet-treated patients achieved a  30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels.
Približno 60 % s cinakalcetom zdravljenih bolnikov je doseglo � 30 % znižanje koncentracije iPTH; tak učinek je bil dosleden prek spektra različnih izhodiščnih koncentracij iPTH.
Approximately 60-70% of the dose was recovered in the urine as active substance.
Približno 60 do 70% odmerka je bilo izmerjenega v urinu v obliki zdravilne učinkovine.
Approximately 62% of ranolazine is bound to plasma proteins, and therefore, complete clearance by haemodialysis is unlikely.
Približno 62 % ranolazina je vezanega na beljakovine v plazmi, zato popolna odstranitev s hemodializo ni verjetna.
Approximately 65% of an i.v. dose is renally excreted within the first 24 hours.
Približno 65 % intravenskega odmerka se izloči skozi ledvice v prvih 24 urah.
Approximately 68% of patients in Group A and 63% of patients in Group B had been treated with dabigatran 110 mg twice daily.
Približno 68 % bolnikov iz skupine A in 63 % bolnikov iz skupine B je bilo zdravljenih z dabigatranom 110 mg dvakrat dnevno.
Approximately 6–16% of the administered dose was excreted in the urine as unchanged drug.
Približno 6-16 % danega odmerka se je izločilo v urinu v obliki nespremenjenega zdravila.
Approximately 7% of an oral dose is excreted as unchanged 6– mercaptopurine within 12 hours after administration.
Približno 7 % peroralnega odmerka se izloča kot nespremenjen 6-merkaptopurin v 12 urah po uporabi.
Approximately 7-8% of individuals of Caucasian descent, 3-6% of Black African descent, 2-3% of Arab descent and 1-2% of Asian descent generally lack the capacity to metabolize CYP2D6 substrates and are classified as Poor Metabolizer (PMs).
Približno 7–8 % posameznikov kavkazijskega porekla, 3–6 % posameznikov afriškega črnega porekla, 2–3 % posameznikov arabskega porekla in 1–2 % posameznikov azijskega porekla v splošnem primanjkuje sposobnosti za presnavljanje substratov CYP2D6 in so označeni kot osebe s slabo presnovo.
Approximately 70 % of patients treated with Rebif can expect to experience the typical interferon flu-like syndrome within the first six months after starting treatment.
Približno 70 % bolnikov zdravljenih z zdravilom Rebif lahko pričakuje pojav za interferon značilnega gripi podobnega sindroma v prvih šestih mesecih po začetku zdravljenja.
Approximately 70 g of glucose was excreted in the urine per day (corresponding to 280 kcal/day) at a dapagliflozin dose of 10 mg/day in subjects with type 2 diabetes mellitus for 12 weeks.
Med 12- tedensko uporabo 10 mg dapagliflozina na dan se je pri bolnikih s sladkorno boleznijo tipa 2 v urinu izločilo približno 70 g glukoze na dan (to ustreza 280 kcal/dan).
Approximately 70 patients from study EGF114299 who have been randomised to the lapatinib + AI arm with an exposure of approximately 6 months.
Približno 70 bolnikov iz študije EGF114299, randomiziranih v krak z lapatinibom + AI z izpostavljenostjo približno 6 mesecev.
Approximately 70–80% of pirfenidone is metabolised via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6, and 2E1.
Okoli 70–80 % pirfenidona se presnavlja preko CYP1A2, medtem ko drugi izoencimi CYP, vključno s CYP2C9, 2C19, 2D6 in 2E1, k presnovi pirfenidona prispevajo manj.
Approximately 70–80% of pirfenidone is metabolised via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6, and 2E1.
Približno 70–80 % pirfenidona se presnavlja preko CYP1A2, medtem ko drugi izoencimi CYP, vključno s CYP2C9, 2C19, 2D6 in 2E1, k presnovi pirfenidona prispevajo manj.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Pribliţno 75 % vnesenega odmerka se izloči z blatom, preostala količina pa z urinom.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Približno 75 % zaužitega odmerka se izloči z blatom, preostalo pa z urinom.
Approximately 75% of patients who respond satisfactorily to treatment require a dose of ≤ 9.6 μg/day.
Približno 75 % bolnikov, ki zadovoljivo odgovorijo na zdravljenje, potrebuje odmerek, ki je  9,6 µg/dan.
Approximately 78% of the subjects on 20 mg esomeprazole reported first resolution of heartburn within the first week of treatment compared to 52 – 58% for placebo.
Približno 78 % preiskovancev, ki so dobivali 20 mg esomeprazola, je poročalo o prvem prenehanju zgage v prvem tednu zdravljenja v primerjavi z 52–58 % preiskovancev, ki so dobivali placebo.
Approximately 8% of patients had a severe ADR (common toxicity criteria, (CTC) grade 3 or 4).
Približno 8 % bolnikov je imelo hude neželene učinke (3. ali 4. stopnjo po Skupnih merilih toksičnosti [common toxicity criteria], CTC).
Approximately 80 - 100 % of the medicinal product is excreted by the kidneys within 24 hours as the conjugated product, phenylacetylglutamine.
Približno 80–100 % zdravila se izloči preko ledvic v 24 urah v obliki konjugiranega produkta, fenilacetilglutamina.
Approximately 80% of AR episodes occurred by Month 3 and were infrequent after Month 6.
Približno 80 % primerov akutne zavrnitve se je zgodilo do 3. meseca, po
Approximately 80% of patients developed neutralizing antibodies capable of inhibiting the elosulfase alfa from binding to the cation- independent mannose-6-phosphate receptor.
Približno 80 % bolnikov je razvilo nevtralizirajoča protitelesa, ki zavirajo vezavo elosulfaze alfa na od kationov neodvisni receptor za manozo-6-fosfat.
Approximately 80% of the dose was recovered in the urine and 15% in the faeces.
Približno 80% odmerka se je pojavilo v urinu in 15% v blatu.
Approximately 85% of patients receiving LEMTRADA tested positive for anti-alemtuzumab antibodies during the study, with 92% of these patients testing positive also for antibodies that inhibited LEMTRADA binding in vitro.
Približno 85 % bolnikov, ki je prejelo zdravilo LEMTRADA v študiji, je imelo pozitiven rezultat določitve protiteles proti alemtuzumabu, 92 % od njih pa je imelo tudi pozitiven rezultat za protitelesa, ki so zavirala vezavo zdravila LEMTRADA in vitro.
Approximately 90% of 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces.
Približno 90 % odmerka, označenega s 14C, se izloči skozi ledvice, medtem ko v blatu najdemo manj kot 2 % odmerka.
Approximately 90% of 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces.
Približno 90 % odmerka, označenega s 14C, se izloči skozi ledvice, medtem ko v fecesu najdemo manj kot 2 % odmerka.
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
Približno 90 % spinosada sestavljata spinosina A in D. Od teh 90 % je razmerje med spinosinom A in A + D 0,85, če se izračuna kot spinosin A/spinosin A + D. Konsistentnost te številke v farmakokinetičnih in drugih študijah kaže na primerljivost absorpcije, presnove in izločanja dveh glavnih spinosinov.
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
Približno 90 % spinosada sestavljata spinosina A in D. Od teh 90 % je razmerje spinosina A in spinosina A in D 0,85, če se izračuna kot spinosin A/spinosin A in D. Doslednost te številke v farmakokinetičnih in drugih študijah kaže na primerljivost absorpcije, presnove in izločanja dveh glavnih spinosinov.
Approximately 96-98% of midazolam is bound to plasma proteins.
Približno 96–98% midazolama se veže na beljakovine plazme.
Approximately 98 % of meloxicam is bound to plasma proteins.
Približno 98 % meloksikama se veže na beljakovine v plazmi.
Approximately 98% of meloxicam is bound to plasma proteins.
Približno 98% meloksikama se veže na beljakovine v plazmi.
Approximately 9–17 % of patients treated with Taltz at the recommended dosing regimen developed anti-drug antibodies, the majority of which were low titres and not associated with reduced clinical response up to 60 weeks of treatment.
Pri približno 9–17 % bolnikov, zdravljenih z zdravilom Taltz po priporočenem režimu odmerjanja, so se razvila protitelesa proti zdravilu, od katerih je imela večina nizke titre in niso bila povezana z zmanjšanim kliničnim odzivom v obdobju do 60 tednov zdravljenja.
Approximately forty-eight percent of patients continued on stable doses of methotrexate (≤ 25 mg/week).
Dovoljeni so bili sočasni ustaljeni odmerki peroralnih aminosalicilatov in/ali imunomodulatorjev.
Approximately half of the patients had at least 3 years of prior exposure to Viramune immediate-release prior to entering study 1100.1526.
Približno polovica bolnikov je pred sprejemom v študijo 1100.1526 že najmanj 3 leta prejemala zdravilo Viramune.
Approximately half of the patients who developed an ANC < 1 x 109/ l did so within 8 weeks after starting therapy.
Med bolniki, ki se jim je absolutno število nevtrofilcev zmanjšalo na < 1 x 109/l, se je to pri približno polovici zgodilo v 8 tednih po začetku zdravljenja.
Approximately half of those infections were Grade 3 or 4; 24.0% in Pom + LD-Dex-treated patients and 22.8% in patients who received HD-Dex.
Približno polovica okužb je bila 3. ali 4. stopnje; 24,0 % bolnikov, zdravljenih s Pom + NO-deks, in 22,8 % bolnikov, ki so prejemali VO-deks.
Approximately half the patients in each treatment group had ER-positive and/or PgR-positive disease.
Približno polovica bolnic v vsaki zdravljeni skupini je imela prisotne ER in/ali PgR v tumorjih.
Approximately half the patients in each treatment group had hormone receptor-positive disease (defined as ER positive and/or PgR positive).
Približno polovica bolnic v vsaki zdravljeni skupini je imela hormonsko odvisen karcinom (opredeljen s pozitivnimi ER in/ali PgR).
Approximately half the patients in each treatment group had hormone receptor-positive disease (defined as estrogen receptor (ER) positive and/or progesterone receptor (PgR) positive) and approximately half of the patients in each treatment group had received prior adjuvant or neoadjuvant therapy.
Približno polovica bolnikov v vsaki od obeh terapevtskih skupin je imela hormonsko odvisen karcinom (opredeljen s pozitivnimi estrogenskimi receptorji (ER) in/ali progesteronskimi receptorji (PgR)) in približno polovica bolnikov v vsaki od obeh terapevtskih skupin je predhodno prejemala adjuvantno ali neoadjuvantno zdravljenje.
Approximately half the radioactivity administered orally as [14C]­netupitant was recovered from urine and faeces within 120 h of dosing.
Približno polovico radioaktivnosti, peroralno dane v obliki [14C]-netupitanta, so odkrili v urinu in blatu v 120 urah od odmerjanja.
Approximately one third of patients can be expected to experience adverse reactions following treatment with tenofovir disoproxil fumarate in combination with other antiretroviral agents.
Neželeni učinki so za pričakovati pri približno 1/3 bolnikov, zdravljenih z dizoproksiltenofovirijevim fumaratom v kombinaciji z drugimi protiretrovirusnimi zdravili.
Approximately one-third of patients had failed prior TNF antagonist therapy.
Pri približno eni tretjini bolnikov je bilo predhodno zdravljenje z zaviralcem TNFα neuspešno.
Approximately one-third of the patients enrolled (76 [33.8%] in the Ilaris group and 84 [36.7%] in the triamcinolone acetonide group) had documented inability (intolerance, contraindication or lack of response) to use both NSAIDs and colchicine.
Približno ena tretjina vključenih bolnikov (76 [33,8 %] v skupini z zdravilom Ilaris in 84 [36,7 %] v skupini s triamcinolon acetonidom) je imela dokumentirano nezmožnost (neprenašanje, kontraindikacije ali nezadosten učinek) uporabe tako nesteroidnih protivnetnih zdravil kot kolhicina.
Approximately twice the proportion of patients in the placebo group in the first 12 weeks of Studies HS-I and HS-II, compared with those in the Humira group experienced worsening of abscesses (23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively).
Približno dvakratni delež bolnikov v skupini, ki je prejemala placebo, je v primerjevi s tistimi, ki so bili v skupini z zdravilom Humira, je v prvih 12. tednih študije HS-I in HS-II, doživelo poslabšanje abscesov (23,0% v primerjavi z 11,4%, v tem zaporedju) in fistul z izcedkom (30,0 % v primerjavi s 13,9%, v tem zaporedju).
Approximately twice the proportion of patients in the placebo group in the first 12 weeks of Studies HS-I and HS-II, compared with those in the Humira group experienced worsening of abscesses (23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively).
Približno dvakratni delež bolnikov v skupini, ki je prejemala placebo, je v primerjevi s tistimi, ki so bili v skupini z zdravilom Humira, v prvih 12. tednih študije HS-I in HS-II, doživelo poslabšanje abscesov (23,0% v primerjavi z 11,4%, v tem zaporedju) in fistul z izcedkom (30,0 % v primerjavi s 13,9%, v tem zaporedju).
Approximately twice the proportion of patients in the placebo group in the first 12 weeks of Studies HS-I and HS-II, compared with those in the Humira group experienced worsening of abscesses (23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively).
V odprti podaljšani študiji je v oceni prenehanja uporabe in ponovnega zdravljenja sodelovalo skupno 347 stabilnih odzivnih bolnikov.
Approximately two to three fold increases in clobazam and five fold increases in norclobazam plasma levels respectively have been reported with co-administration of stiripentol in children with Dravet’s syndrome.
Pri sočasnem dajanju stiripentola otrokom z Dravetovim sindromov so opazili približno dva- do trikratno zvišanje plazemskih koncentracij klobazama in petkratno zvišanje plazemskih koncentracij norklobazama.
Apr  Aug  Dec
Apr  Avg  Dec
Apremilast 30 mg BID
apremilast 30 mg dvakrat na dan
Apremilast administered at doses of up to 50 mg BID did not prolong the QT interval in healthy subjects.
Apremilast, ki so ga dajali v odmerkih do 50 mg dvakrat na dan, pri zdravih preiskovancih ni podaljševal intervala QT.
Apremilast can be co-administered with a potent CYP3A4 inhibitor such as ketoconazole.
Apremilast lahko dajemo sočasno z močnim zaviralcem CYP3A4, na primer ketokonazolom.
Apremilast has no influence on the ability to drive and use machines.
Apremilast ne vpliva na sposobnost vožnje in upravljanja s stroji.
Apremilast is contraindicated during pregnancy.
Apremilast je med nosečnostjo kontraindiciran.
Apremilast is extensively metabolised by both CYP and non-CYP mediated pathways including oxidation, hydrolysis, and conjugation, suggesting inhibition of a single clearance pathway is not likely to cause a marked drug-drug interaction.
Apremilast obsežno presnavljajo tako presnovne poti, ki jih posreduje CYP, kot tiste, ki jih CYP ne posreduje, vključno z oksidacijo, hidrolizo in konjugacijo, kar kaže na to, da inhibicija ene same poti za odstranjevanje apremilasta verjetno ne bo povzročila znatne interakcije med zdravili.
Apremilast was detected in milk of lactating mice (see section 5.3).
Apremilast so našli v mleku doječih miši (glejte poglavje 5.3).
Apremilast was not clastogenic in an in vivo mouse micronucleus assay at doses up to 2000 mg/kg/day.
Apremilast ni bil klastogen v mišjem mikronukleusnem testu in vivo v odmerkih do 2.000 mg/kg/dan.
Apremilast was studied in healthy subjects at a maximum total daily dose of 100 mg (given as 50 mg BID) for 4.5 days without evidence of dose limiting toxicities.
Apremilast so proučevali pri zdravih preiskovancih v največjem celotnem dnevnem odmerku 100 mg (dan v odmerku 50 mg dvakrat na dan) 4,5 dni brez znakov toksičnosti, ki bi omejevala odmerek.